Ivakaftor
Ivakaftor
Klass : 2
Visa all info
Skriv ut
Kontakta oss
SPC Kalydeco http://goo.gl/48TJPg
EMA. Kalydeco. CHMP Assessment report; 2012 http://goo.gl/vIoApt
Sermet-Gaudelus I. Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation. Eur Respir Rev. 2013;22:66-71.
Qiu F, Habgood M, Schneider-Futschik EK. The Balance between the Safety of Mother, Fetus, and Newborn Undergoing Cystic Fibrosis Transmembrane Conductance Regulator Treatments during Pregnancy. ACS Pharmacol Transl Sci. 2020;3(5):835-843.
Kaminski R, Nazareth D. A successful uncomplicated CF pregnancy while remaining on Ivacaftor. J Cyst Fibros. 2016;15:133-4.
Ladores S, Kazmerski TM, Rowe SM. A Case Report of Pregnancy During Use of Targeted Therapeutics for Cystic Fibrosis. J Obstet Gynecol Neonatal Nurs. 2016;46(1):72-77.
Trimble A, McKinzie C, Terrell M, Stringer E, Esther CR. Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding. J Cyst Fibros. 2018;17(6):779-782.
Nash EF, Middleton PG, Taylor-Cousar JL. Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey. J Cyst Fibros. 2020;19(4):521-526.
Taylor-Cousar JL, Jain R. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J Cyst Fibros. 2021;20(3):402-406.
Jain R, Wolf A, Molad M, Taylor-Cousar J, Esther CR, Shteinberg M. Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding. J Cyst Fibros. 2022;21(6):1074-1076.
- SPC Kalydeco http://goo.gl/48TJPg
- EMA. Kalydeco. CHMP Assessment report; 2012 http://goo.gl/vIoApt
- Sermet-Gaudelus I. Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation. Eur Respir Rev. 2013;22:66-71.
- Qiu F, Habgood M, Schneider-Futschik EK. The Balance between the Safety of Mother, Fetus, and Newborn Undergoing Cystic Fibrosis Transmembrane Conductance Regulator Treatments during Pregnancy. ACS Pharmacol Transl Sci. 2020;3(5):835-843.
- Kaminski R, Nazareth D. A successful uncomplicated CF pregnancy while remaining on Ivacaftor. J Cyst Fibros. 2016;15:133-4.
- Ladores S, Kazmerski TM, Rowe SM. A Case Report of Pregnancy During Use of Targeted Therapeutics for Cystic Fibrosis. J Obstet Gynecol Neonatal Nurs. 2016;46(1):72-77.
- Trimble A, McKinzie C, Terrell M, Stringer E, Esther CR. Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding. J Cyst Fibros. 2018;17(6):779-782.
- Nash EF, Middleton PG, Taylor-Cousar JL. Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey. J Cyst Fibros. 2020;19(4):521-526.
- Taylor-Cousar JL, Jain R. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J Cyst Fibros. 2021;20(3):402-406.
- Jain R, Wolf A, Molad M, Taylor-Cousar J, Esther CR, Shteinberg M. Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding. J Cyst Fibros. 2022;21(6):1074-1076.